Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide’s effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS: This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [SURPASS-1] and A Study of Tirzepatide [LY3298176] Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [SURPASS-2]) or week 52 (A Study of Tirzepatide [LY3298176] Versus Insulin Degludec in Participants With Type 2 Diabetes [SURPASS-3]). Analyses were performed by study on data from participants while on assigned treatment without rescue medication in case of persistent hyperglycemia. RESULTS: At baseline in SURPASS-2, participants with early-onset versus later-onset T2D were younger with longer diabetes duration (9 vs. 7 years, P < 0.001) higher glycemic levels (8.5% vs. 8.2%, P < 0.001), higher BW (97 vs. 93 kg, P < 0.001) and BMI (35 vs. 34 kg/m2, P < 0.001), and a similarly abnormal lipid profile (e.g., triglycerides 167 vs. 156 mg/dL). At week 40, similar improvements in HbA1c (−2.6% vs. −2.4%), BW (−14 vs. −13 kg), WC (−10 vs. −10 cm), triglycerides (−26% vs. −24%), HDL (7% vs. 7%), and systolic BP (−6 vs. −7 mmHg) were observed in both subgroups with tirzepatide. CONCLUSIONS: Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, only two RCTs have reported data surrounding the effectiveness of pharmacological treatment in adults with EOT2D in sub-analyses of larger RCTs [65,66].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationType 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Laiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Sattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A.-M., Rosengren, A., McGuire, D. K., Eliasson, B., & Gudbjörnsdottir, S. (2019) · Circulation · doi:10.1161/circulationaha.118.037885 · Cited by 555
Long-term complications in youth-onset type 2 diabetes
TODAY Study Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100165 · Cited by 546
Young-onset type 2 diabetes mellitus — implications for morbidity and mortality
Magliano, D. J., Sacre, J. W., Harding, J. L., Gregg, E. W., Zimmet, P. Z., & Shaw, J. E. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0334-z · Cited by 483
Long-Term Complications and Mortality in Young-Onset Diabetes
Constantino, M. I., Molyneaux, L., Limacher-Gisler, F., Al-Saeed, A., Luo, C., Wu, T., Twigg, S. M., Yue, D. K., & Wong, J. (2013) · Diabetes Care · doi:10.2337/dc12-2455 · Cited by 423
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
Nadeau, K. J., Anderson, B. J., Berg, E. G., Chiang, J. L., Chou, H., Copeland, K. C., Hannon, T. S., Huang, T. T.-K., Lynch, J. L., Powell, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1066 · Cited by 381
Self-citationArslanian, S., Bacha, F., Grey, M., Marcus, M. D., White, N. H., & Zeitler, P. (2018) · Diabetes Care · doi:10.2337/dci18-0052 · Cited by 349
Self-citationHeise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
The RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0787 · Cited by 176
Self-citationRosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., Fernández Landó, L., & Patel, H. (2023) · JAMA · doi:10.1001/jama.2023.20294 · Cited by 156
Lingvay, I., Mosenzon, O., Brown, K., Cui, X., O’Neill, C., Fernández Landó, L., & Patel, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01797-5 · Cited by 55
Lee, C. J., Mao, H., Thieu, V. T., Landó, L. F., & Thomas, M. K. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad056 · Cited by 47
Self-citationAchieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
Rosenstock, J., Vázquez, L., Del Prato, S., Franco, D. R., Weerakkody, G., Dai, B., Landó, L. F., Bergman, B. K., & Rodríguez, A. (2023) · Diabetes Care · doi:10.2337/dc23-0872 · Cited by 45
Self-citation
Research works printed but not linked: 18
- Viner, 2017, Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden, Lancet, 389, 2252, 10.1016/S0140-6736(17)31371-5 · DOI · Paper page
- Lawrence, 2021, Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017, JAMA, 326, 717, 10.1001/jama.2021.11165 · DOI · Paper page
- Lawrence, 2014, Incidence of diabetes in United States youth by diabetes type, race/ethnicity, and age, 2008–2009, Diabetes, 63, A407
- Dabelea, 2014, Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009, JAMA, 311, 1778, 10.1001/jama.2014.3201 · DOI · Paper page
- Sasidharan Pillai, 2023, Incidence, severity, and presentation of type 2 diabetes in youth during the first and second year of the COVID-19 pandemic, Diabetes Care, 46, 953, 10.2337/dc22-1702 · DOI
- Magge, 2022, The coronavirus disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes, J Pediatr, 251, 51, 10.1016/j.jpeds.2022.08.010 · DOI
- TODAY Study Group, 2012, A clinical trial to maintain glycemic control in youth with type 2 diabetes, N Engl J Med, 366, 2247, 10.1056/NEJMoa1109333 · DOI · Paper page
- Lee, 2023, Earlier age at type 2 diabetes diagnosis is associated with increased genetic risk of cardiovascular disease, Diabetes Care, 46, 1085, 10.2337/dc22-2144 · DOI
- Al-Saeed, 2016, An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes, Diabetes Care, 39, 823, 10.2337/dc15-0991 · DOI · Paper page
- Emerging Risk Factors Collaboration, 2023, Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation, Lancet Diabetes Endocrinol, 11, 731, 10.1016/S2213-8587(23)00223-1 · DOI · Paper page
- Sargeant, 2020, Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials, Diabetologia, 63, 1516, 10.1007/s00125-020-05174-9 · DOI · Paper page
- Misra, 2023, Current insights and emerging trends in early-onset type 2 diabetes, Lancet Diabetes Endocrinol, 11, 768, 10.1016/S2213-8587(23)00225-5 · DOI · Paper page
- Rosenstock, 2021, Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial, Lancet, 398, 143, 10.1016/S0140-6736(21)01324-6 · DOI · Paper page
- Utzschneider, 2021, Differential loss of β-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study, Diabetes Res Clin Pract, 178, 108948, 10.1016/j.diabres.2021.108948 · DOI
- Sam, 2021, Baseline predictors of glycemic worsening in youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes in the Restoring Insulin Secretion (RISE) study, Diabetes Care, 44, 1938, 10.2337/dc21-0027 · DOI
- TODAY Study Group, 2023, Effect of early glycemic control in youth-onset type 2 diabetes on longer-term glycemic control and β-cell function: results from the TODAY study, Diabetes Care, 46, 1507, 10.2337/dc23-0560 · DOI
- Zeitler, 2022, Deterioration of glycemic control in youth-onset type 2 diabetes: What are the early and late predictors, J Clin Endocrinol Metab, 107, e3384, 10.1210/clinem/dgac254 · DOI
- Klingensmith, 2016, Pregnancy outcomes in youth with type 2 diabetes: the TODAY study experience, Diabetes Care, 39, 122, 10.2337/dc15-1206 · DOI · Paper page
Cited by
Liu, S., Hu, J., Zhao, C., Liu, H., & He, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1513641 · Cited by 17
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
Self-citationDesigning a regional clinical service for people with early‐onset type 2 diabetes in England
Goldney, J., Alabraba, V., Sarkar, P., Morgan, H., Hamza, M., Skarlatos, M., Slater, T., Sargeant, J. A., O'Callaghan, R., Hadjiconstantinou, M., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.15479 · Cited by 7
Self-citation
Metadata
- Authors
- Zeitler, P., Galindo, R. J., Davies, M. J., Bergman, B. K., Thieu, V. T., Nicolay, C., Allen, S., Heine, R. J., & Lee, C. J.
- Affiliations
- 1Children’s Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO
- 2University of Miami Miller School of Medicine, Miami, FL
- 3Diabetes Research Centre, University of Leicester and the Leicester NIHR Biomedical Research Centre, Leicester General Hospital, Leicester, U.K.
- 4Eli Lilly and Company, Indianapolis, IN
- ORCID
- Lee, Clare J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-04-19
- Volume
- 47
- Issue
- 6
- Pages
- 1056-1064
- ISSN
- 0149-5992
- 1935-5548
- Cited by
- 14
- References
- 18
- Language
- en
- Funders
- Eli Lilly and Company
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.